MRD negativity as a surrogate for PFS in CLL?
- PMID: 29496697
- DOI: 10.1182/blood-2018-01-824177
MRD negativity as a surrogate for PFS in CLL?
Conflict of interest statement
Conflict-of-interest disclosure: P.A.T. has served as an advisory board member for Pharmacyclics and Genentech and as a consultant for AbbVie.
Comment on
-
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.Blood. 2018 Mar 1;131(9):955-962. doi: 10.1182/blood-2017-06-792333. Epub 2017 Dec 18. Blood. 2018. PMID: 29255066 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources